Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

  • STATUS
    Recruiting
  • End date
    Sep 23, 2022
  • participants needed
    50
  • sponsor
    Phoenix Molecular Designs
Updated on 23 May 2021
cancer
measurable disease
breast cancer
gilbert's syndrome
neutrophil count
tumor cells
HER2
alopecia
triple negative breast cancer
stage iv breast cancer
erbb2
formalin-fixed paraffin-embedded

Summary

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer and triple negative breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer and triple negative breast cancer.

Description

This study will evaluate the safety and tolerability of PMD-026 using an accelerated titration design to define the MTD in metastatic breast cancer, followed by an expansion at the RP2D in triple negative breast cancer. All patients will receive daily oral doses of PMD-026 until either disease progression or unacceptable toxicity. Patients will have disease assessments initially after 6 weeks of treatment, and every 9 weeks thereafter.

Patients enrolled to the Dose Escalation Phase must have histologically or cytologically diagnosed metastatic breast cancer that has progressed on or after standard of care therapy. Patients enrolled to the Dose Expansion Phase must have histologically or cytologically diagnosed metastatic triple negative breast cancer from initial diagnosis (ER/PgR <1%, HER2 negative) that has progressed on or after standard of care therapy. All patients must provide tumor tissue (archival preferred) prior to study entry.

A subset (N=12) of patients in Part 2 of the study will participate in a 1- week evaluation of the effect of food on PMD-026 oral absorption.

PMD-026 is an oral, reversible small molecule inhibitor of RSK1-4 with high selectivity for RSK2. High levels of RSK2 expression have been associated with worse overall survival in breast cancer. Inhibiting RSK2 may inhibit growth of breast cancer.

Details
Condition Breast Cancer, Diet and Nutrition, Chronic Diarrhea, Skin Wounds, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Metastatic Breast Cancer, Peripheral Arterial Occlusive Disease, Triple Negative Breast Cancer, Stage IV Breast Cancer, Brain Function, Recurrent Respiratory Papillomatosis, Razor Bumps (Pseudofolliculitis Barbae), Metastatic Triple-Negative Breast Cancer
Treatment PMD-026
Clinical Study IdentifierNCT04115306
SponsorPhoenix Molecular Designs
Last Modified on23 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent
Age 18 years
ECOG Performance Status 2
[Part 1 - Dose Escalation] Histologically or cytologically diagnosed metastatic breast cancer that has progressed on or after standard of care therapy and for which no standard of care therapy is available that would confer clinical benefit
[Part 2 - Dose Expansion] Histologically or cytologically diagnosed metastatic triple-negative breast cancer with <1% expression of ER and PR and negative for HER2 (either 0 or 1+ by IHC or IHC 2+ and fluorescence in situ hybridization (FISH) negative) from the time of initial diagnosis that has progressed on or after standard of care therapy and for which no standard of care therapy is available that would confer clinical benefit
[Part 1 - Dose Escalation] Evaluable or measurable disease by RECISTv1.1
[Part 2 - Dose Expansion] Measurable disease by RECISTv1.1
Adequate laboratory parameters including
Absolute Neutrophil Count (ANC) 1500/mm^3
Platelets 100,000/mm^3
AST/SGOT 2.5 x ULN ( 5 x ULN if known liver involvement)
ALT/SGPT 2.5 x ULN ( 5 x ULN if known liver involvement)
Total bilirubin 1.5 x ULN (unless diagnosis of Gilbert's syndrome in which case < 3.0 times ULN)
Serum creatinine 1.5 x ULN or estimated GFR 60 mL/min
If residual treatment related toxicity from prior therapy
Treatment related toxicity resolved to at least Grade 1 (alopecia excepted), or
Treatment related toxicity resolved to at least Grade 2 with prior approval of the Medical Monitor
Available archival or fresh tumor tissue (Formalin-fixed paraffin-embedded [FFPE])
[Females] The patient must be postmenopausal, surgically sterile, or agree to use adequate contraception (adequate as determined by the PI - may include abstinence) throughout the study and for a least 30 days following the last dose of PMD-026
[Males] The patient must be surgically sterile or must agree to use adequate contraception (adequate as determined by the PI - may include abstinence) throughout the study and for at least 30 days following the last dose of PMD-026
[Males] The patient must agree to refrain from donating sperm throughout the study and for at least 30 days following the last dose of PMD-026
[Females] If of childbearing potential, the patient must have a negative serum pregnancy test

Exclusion Criteria

14 days from prior chemotherapy, biological or investigational therapy
Use of any medications known to result in a prolongation of the QT/QTc interval
Use of any medication that is a strong inducer or substrate of cytochrome P450 3A
Use of any medications that is a substrate of BCRP
Use of any medication that is a substrate of MATE2K
28 days from prior irradiation (including therapeutic radioisotopes such as strontium 89)
7 days from limited field irradiation for palliation
28 days from major surgical procedures
7 days from minor surgical procedures (no waiting period required following central catheter placement)
Central nervous system metastases, unless appropriately treated and neurologically stable for 28 days
Known history of leptomeningeal metastases
Uncontrolled bacterial, viral, or fungal infection (s) requiring systemic therapy
Pregnant or currently breast-feeding
Known Hepatitis B or Hepatitis C infection
Known HIV-positive with CD4+ cell counts < 350 cells/uL
Known HIV-positive with a history of an AIDS-defining opportunistic infection
History of clinically significant cardiovascular abnormalities including
Congestive heart failure (NYHA classification 3 in within 6 months of first dose of PMD-026
Unstable angina pectoris
Myocardial infarction within 12 months of study entry
Arrhythmias requiring continued treatment (controlled atrial fibrillation allowed)
QTcF interval > 460 msec (using Fridericia's formula)
Presence of active gastrointestinal disease or other condition that is expected to interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade 2, and malabsorption syndrome)
Inadequately controlled hypertension defined as systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg (patients with values above these levels must have their blood pressure controlled prior to starting treatment)
Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment
Other known active cancer(s) likely to require treatment in the next year that would impact the assessment of any study endpoints
Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note